Glenmark Pharmaceuticals on Tuesday said it has received approval from the U.S. health regulator to market a generic medication to treat psoriatic arthritis in the American market.
The company has received final approval from the U.S. Food & Drug Administration (USFDA) for Apremilast tablets in strength of 10 mg, 20 mg and 30 mg, the Mumbai-based drug maker said in a statement.
The company's product is a generic version of Otezla tablets, it added.
According to IQVIA sales data for the 12-month period ending August 2023, the Otezla tablets (10 mg, 20 mg, and 30 mg) achieved annual sales of around $3.7 billion.
Glenmark said its current portfolio consists of 188 products authorised for distribution in the U.S. market marketplace and 50 abbreviated new drug applications (ANDAs) are pending approval with the USFDA.
Glenmark shares were trading 1.49% up at Rs 809.40 apiece on the BSE.
RECOMMENDED FOR YOU
Alembic Pharma Gets USFDA Nod For Generic Drug To Treat Depression, Anxiety
Sep 25, 2025
Aurobindo Pharma Eyes 'Significant Portion' Of $7 Billion Osteoporosis Drug Market
Sep 23, 2025
USFDA Issues Form 483 With Eight Observations To Aurobindo's Telangana Unit
Sep 05, 2025
India's Tablet Market Dips 32.3% In First Half Of 2025, Samsung Tops Chart
Aug 28, 2025
POPULAR
